UK peptide clinics have been under MHRA review since April 2026, after The Guardian reported that some were promoting unregulated, experimental peptides. The sources for this page report no outcome yet.

Why is the MHRA investigating peptide clinics?

Pharmacy Business says the MHRA "is investigating whether clinics are breaking the law" through claims about experimental peptide therapies. Aesthetics Journal named peptides including BPC-157 and Cortexin. An MHRA spokesperson said: "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012." After The Guardian approached one clinic, "the claims were removed from the site".

What has BCAM said about peptide clinics?

The British College of Aesthetic Medicine issued a public warning in May 2026. Aesthetics Journal reports it said UK rules "prohibit the advertising of unlicensed medicines and prescription-only medicines to the public".

Which law applies?

The guide to the Human Medicines Regulations 2012 sets out the test. On the MHRA's reading, peptide clinics making medicinal claims fall inside it. For one compound, see is BPC-157 legal in the UK.

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.